Retos y avances hacia la medicina de precisión en el mieloma múltiple

Translated title of the contribution: Towards precision medicine in myeloma: New evidence and challenges

Verónica González-Calle, Rafael Fonseca

Research output: Contribution to journalArticlepeer-review


In the last few years, next-generation sequencing studies have provided insights into the mutational landscape of multiple myeloma. The identification of actionable mutations might give a precious opportunity for exploring new targeted therapies. Thus, the implementation of promising precision medicine strategies seems to be closer than ever. Throughout this review we describe the main challenges that should to be dealt with in this new era, in order to achieve the main goal of precision medicine, namely matching patients with their right drug. In addition, we provide a review of the most significant preclinical and clinical studies supporting the implementation of precision medicine nowadays. Finally, we highlight the need of clinical trials to evaluate the security and efficacy of these targeted therapies, as well as to validate predictive biomarkers that may allow an appropriate best-candidate selection and improvement of myeloma patients’ survival and quality of life.

Translated title of the contributionTowards precision medicine in myeloma: New evidence and challenges
Original languageSpanish
Pages (from-to)222-226
Number of pages5
Issue number3
StatePublished - Jun 2017


  • Driver mutation
  • Multiple myeloma
  • Personalized medicine
  • Targeted therapy

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Towards precision medicine in myeloma: New evidence and challenges'. Together they form a unique fingerprint.

Cite this